Daniel J Farkas

Troriluzole inhibits methamphetamine place preference in rats and normalizes methamphetamine-evoked glutamate carboxypeptidase II (GCPII) protein levels in the mesolimbic pathway.

A. Reitz, S. Rawls, Mia N. Watson, 2022, Drug and alcohol dependence.

Multi-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and normalizes opioid-induced dysregulation of mesolimbic chemokine receptors in rats.

M. Wimmer, S. Rawls, Mia N. Watson, 2022, Drug and alcohol dependence.

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

D. Brenneman, W. Kinney, S. Ward, 2021, British journal of pharmacology.

Mitragynine, bioactive alkaloid of kratom, reduces chemotherapy-induced neuropathic pain in rats through α-adrenoceptor mechanism.

S. Rawls, S. Ward, S. Nayak, 2020, Drug and alcohol dependence.

Purinergic P2X7 receptor antagonist inhibits methamphetamine-induced reward, hyperlocomotion, and cortical IL-7A levels in mice: A role for P2X7/IL-17A crosstalk in methamphetamine behaviors?

T. Eisenstein, J. Meissler, Taylor A. Gentile, 2022, Brain, Behavior, and Immunity.

Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain.

H. Bradshaw, S. Rawls, S. Ward, 2023, Life sciences.

Kratom alkaloid mitragynine: Inhibition of chemotherapy-induced peripheral neuropathy in mice is dependent on sex and active adrenergic and opioid receptors

S. Rawls, S. Ward, Jeffery D. Foss, 2022, IBRO neuroscience reports.

Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy.

Z. Cooper, S. Rawls, S. Ward, 2023, Cannabis and cannabinoid research.